



DOCKET NO: M00656.70064.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Frank B. Gertler, et al.
Serial No: 09/823,240
Confirmation No: 6318
Filed: March 30, 2001
For: METHODS AND PRODUCTS FOR REGULATING CELL
MOTILITY
Examiner: Terry Alan McKelvey
Art Unit: 1636

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 25th day of November, 2002.

Helen C. Lockhart

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL

Transmitted herewith are the following documents:

- ☒ Amendment;
- ☒ Marked-up Figure 2; and
- ☒ Return Receipt Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No check is enclosed. If any amount is due with this filing, please charge the amount to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:

Helen C. Lockhart, Ph.D., Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Atty Docket No: M00656.70064.US
November 25, 2002

RECEIVED

DEC 05 2002

TECH CENTER 1600/2900



DOCKET NO: M00656.70064.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Frank B. Gertler, et al.
Serial No: 09/823,240
Confirmation No: 6318
Filed: March 30, 2001
For: METHODS AND PRODUCTS FOR REGULATING CELL MOTILITY
Examiner: Terry Alan McKelvey
Art Unit: 1636

#12B
Lita
12-13-02

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 25th day of November, 2002.

Helen C. Lockhart

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

DEC 05 2002

TECH CENTER 1600/2900

Sir:

AMENDMENT

In response to the Office Action mailed October 2, 2002, please amend the above-identified application as follows:

In the Specification

Applicant presents a clean copy of the changes to the specification below and encloses a marked-up copy of the changes to the specification with bracketing and underlining.

Please delete the paragraph beginning at Page 8, Line 7 through line 16 and replace it with the following:

3¹
In some preferred embodiments the functional Ena/VASP protein is induced by contacting the mammalian cell with an Ena/VASP activator. The Ena/VASP activator can be a plasma membrane targeting compound that targets the endogenous Ena/VASP protein to the plasma membrane or in other embodiments it can be exogenous Ena/VASP protein. The